Many innovative new therapies are coming onto the market as drugmakers continue to gain insight into biomarkers and how to drill down into subsets of diseases. But these products also are launching with increasingly higher price tags, even as lawmakers and regulators launch a flurry of activity aimed at bringing down drug prices. Some industry experts caution that a few of the bills, if passed, could endanger the research and development efforts around these novel drugs, while others question that hypothesis.
- Datapoint, Medicare and Medicaid
- Abstract, Drug Benefits
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits